Management of Borderline High Triglycerides

Classification and Risk Assessment

A triglyceride level of 159 mg/dL is classified as "borderline high" according to the American Heart Association guidelines (150-199 mg/dL) 1
Borderline high triglycerides have been established as an independent risk factor for coronary heart disease (CHD) through meta-analyses of prospective studies 2, 3
This level is associated with increased cardiovascular risk but is below the threshold for concern about pancreatitis risk (which typically occurs at levels >1000 mg/dL) 1

Evaluate for secondary causes of hypertriglyceridemia, including uncontrolled diabetes, medications (corticosteroids, estrogens, antipsychotics, antiretrovirals), and family history of dyslipidemia 1, 4
Assess for other cardiovascular risk factors (obesity, hypertension, abnormal glucose metabolism) 1
Evaluate for features of metabolic syndrome, which is closely linked to hypertriglyceridemia 2, 5

Implement intensive therapeutic lifestyle changes, which can reduce triglyceride levels by up to 50% 4
Weight loss: Target a 5-10% reduction in body weight, which can reduce triglycerides by approximately 20% 1
Dietary modifications: Reduce carbohydrate intake, especially refined carbohydrates and added sugars, eliminate dietary trans fatty acids, and moderate fat intake with emphasis on unsaturated fats 1, 4
Physical activity: Aim for at least 150 minutes per week of moderate-intensity aerobic activity 1
Reduce or eliminate alcohol consumption 4

For borderline high triglycerides (150-199 mg/dL), pharmacological therapy is generally not the first-line approach unless other cardiovascular risk factors are present 1
If triglycerides remain elevated after 3 months of lifestyle modifications and the patient has other cardiovascular risk factors, consider statins if LDL-C is also elevated (primary target) 4

While triglyceride levels are a biomarker for cardiovascular risk, there is insufficient evidence that lowering triglyceride levels alone improves cardiovascular outcomes beyond addressing LDL-C 1
Triglyceride measurements can vary considerably for individual patients, so decisions should not be based on a single measurement 3
The primary target of therapy in all persons with borderline triglycerides should be LDL cholesterol; ATP III guidelines for diet, exercise, and drug therapy should be followed to achieve the LDL cholesterol goal first 3, 5
Abdominal obesity (waist circumference >102 cm in men or >88 cm in women) particularly increases cardiovascular risk and should be addressed 5